This meta-analysis assessed the efficacy and safety of iclaprim compared with those of vancomycin in the treatment of acute bacterial skin and skin structure infection (ABSSSI). Only randomized controlled trials (RCTs) comparing the effect of iclaprim with vancomycin on adult patients with ABSSSIs were included. A total of 3 RCTs involving 1260 adult patients with ABSSSIs were enrolled. Iclaprim had a non-inferior clinical response rate compared with vancomycin. Similar trend was observed in the following subgroups: major cutaneous abscesses, cellulitis/erysipelas, wound infections, MRSA, MSSA, Streptococcus pyogenes infections. Finally, no differences were observed between iclaprim and vancomycin regarding the risks of any AE, drug-related AE, severe AE, discontinuation of study drug due to AE, and mortality. In conclusion, iclaprim exhibits non-inferior efficacy compared with vancomycin in the treatment of ABSSSI. Additionally, iclaprim was generally as well tolerated as vancomycin.
Key words: Iclaprim, vancomycin, acute bacterial skin and skin structure infection
|
